Evidence map›Paper›PMID 25812041›Full record

ReviewGenetics in medicine : official journal of the American College of Medical Genetics2016

Difficulties in diagnosing Marfan syndrome using current FBN1 databases.

Kristian A Groth, Mette Gaustadnes, Kasper Thorsen, John R Østergaard, Uffe Birk Jensen, Claus H Gravholt, Niels H Andersen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Genetics in medicine : official journal of the American College of Medical Genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06257004 (Genome-wide Epistasis for Cardiovascular Severity in Marfan Study), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06257004 unknown statusnot on this mapstarted 2020, after this paper: background citation

Genome-wide Epistasis for Cardiovascular Severity in Marfan Study

TypeobservationalSponsorUniversity Hospital, AntwerpRan2020 to 2025Enrolled200ConditionsMarfan Syndrome, FBN1 MutationArmsSaliva collection (screening of all participants), Bloodsampling
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. The Molecular Genetics of Marfan Syndrome.International journal of medical sciences · 2021
    Review
  4. Genomic Screening: The Mutation and the Mustard Seed.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2018
    Article
  5. Article
  6. Article
  7. Evaluating the quality of Marfan genotype-phenotype correlations in existing FBN1 databases.Genetics in medicine : official journal of the American College of Medical Genetics · 2017
    Article
  8. Aortic events in a nationwide Marfan syndrome cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kristian A GrothDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0002-3452-8298
Mette GaustadnesDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Kasper ThorsenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-0195-4685
John R ØstergaardCentre for Rare Diseases, Department of Paediatrics, Aarhus University Hospital, Aarhus, Denmark.
Uffe Birk JensenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Claus H GravholtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Niels H AndersenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Funding

NHLBI NIH HHS HL-102923NHLBI NIH HHS HL-102924NHLBI NIH HHS HL-102925NHLBI NIH HHS HL-102926NHLBI NIH HHS HL-103010
6 · The paper itself

Abstract

purposeThe diagnostic criteria of Marfan syndrome (MFS) highlight the importance of a FBN1 mutation test in diagnosing MFS. As genetic sequencing becomes better, cheaper, and more accessible, the expected increase in the number of genetic tests will become evident, resulting in numerous genetic variants that need to be evaluated for disease-causing effects based on database information. The aim of this study was to evaluate genetic variants in four databases and review the relevant literature.

methodsWe assessed background data on 23 common variants registered in ESP6500 and classified as causing MFS in the Human Gene Mutation Database (HGMD). We evaluated data in four variant databases (HGMD, UMD-FBN1, ClinVar, and UniProt) according to the diagnostic criteria for MFS and compared the results with the classification of each variant in the four databases.

resultsNone of the 23 variants was clearly associated with MFS, even though all classifications in the databases stated otherwise.

conclusionA genetic diagnosis of MFS cannot reliably be based on current variant databases because they contain incorrectly interpreted conclusions on variants. Variants must be evaluated by time-consuming review of the background material in the databases and by combining these data with expert knowledge on MFS. This is a major problem because we expect even more genetic test results in the near future as a result of the reduced cost and process time for next-generation sequencing.Genet Med 18 1, 98-102.

Indexed as

Databases, GeneticFibrillinsGenetic VariationHigh-Throughput Nucleotide SequencingHumansMarfan SyndromeMicrofilament ProteinsMutationFibrillinsMicrofilament Proteins

Identifiers

PMID25812041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.